[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Swedish Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":113},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,75,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100601297","machine-learning-prediction-of-possible-central-line-associated-blood-stream-infections-and-rate-of-reduction-100601297",false,"NCT07108660","Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction","Prediction and Reduction of Central Line Associated Blood Stream Infections: A Machine Learning Improvement Study","CLABSI AI","Inclusion Criteria:\n\n* The top twenty Providence St. Joseph Health Hospitals by CLABSI burden.\n\nExclusion Criteria:\n\n* Less than 18 years of age","ALL","18 Years",{"count":20,"type":21},17800,"ESTIMATED","INTERVENTIONAL",[24],"NA","Prospective, multi-center, cluster-randomized trial of a hospital Infection Preventionist (IP)-led quality improvement study to provide clinical teams with just-in-time clinical education and reinforcement of existing best practices recommendations based on the output of a possible Central Line Associated Blood Stream Infection (CLABSI) Machine Learning (ML) prediction model.\n\nThe objective is to determine whether providing this model to Infection Preventionists will decrease the CLABSI rates versus routine clinical practice.",[27],"Central Line Associated Blood Stream Infections (CLABSI)",[29,30,31,32,33,34,35,36],"Inpatient","CLABSI","Central Line Associates Blood Stream Infections","Infection Prevention","Artificial Intelligence","Machine Learning","Healthcare Associated Infection","HAI","RECRUITING","2025-08-12",{"date":40,"type":41},"2025-08-15","ACTUAL",{"date":43,"type":41},"2025-07-01",{"date":45,"type":21},"2027-12",{"name":47,"class":48},"Swedish Medical Center","OTHER",19,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100508877","phase-1-minimally-invasive-esophagectomy-pain-control-trial-100508877","NCT05906134","Minimally Invasive Esophagectomy Pain Control Trial","A Randomized Controlled Trial Comparing Local Intercostal Nerve Blocks, Cryo-ablation Plus Intercostal Nerve Blocks, and Serratus Plane Catheter Plus Intercostal Nerve Blocks After Minimally Invasive Esophagectomy","Inclusion Criteria:\n\nAll adult individuals who undergo an esophagectomy with an intended minimally invasive approach of the chest at Swedish Medical Center-First Hill. These approaches include:\n\n* 3-hole with R video-assisted thoracoscopic surgery (VATS)\n* Ivor Lewis R VATS\n\nExclusion Criteria:\n\n* Age \\\u003C18\n* Unable to consent\n* Additional surgical procedures planned\n* Patients with previous thoracic surgery\n* Patient with chronic pain on a daily regimen of narcotics\n* Non-English speaking\n* Contraindications to neuraxial anesthesia (ongoing anticoagulation, anticipated post-operative therapeutic anticoagulation, spinal cord stimulators, anatomic abnormalities preventing epidural placement)",{"count":58,"type":21},30,[60,61],"PHASE1","PHASE2","A pilot randomized controlled trial comparing intercostal nerve blocks, cryo-ablation plus intercostal nerve blocks, and serratus plane catheter plus intercostal nerve blocks in patients undergoing esophagectomies with minimally invasive thoracic approaches.",[64,65],"Postoperative Pain, Acute","Postoperative Complications","2025-07-17",{"date":68,"type":41},"2025-07-23",{"date":70,"type":41},"2022-04-26",{"date":72,"type":21},"2027-02",{"name":47,"class":48},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":74},"100547704","early-chest-tube-removal-after-surgery-for-primary-spontaneous-pneumothorax-a-randomized-controlled-trial-100547704","NCT06411431","Early Chest Tube Removal After Surgery for Primary Spontaneous Pneumothorax: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patient undergoing video assisted thoracoscopic surgery with blebectomy\u002Fwedge resection and chemical pleurodesis for primary spontaneous pneumothorax\n* Adult patients (\\> 18 years)\n\nExclusion Criteria:\n\n* Subjects with history of chest radiation or prior ipsilateral chest surgery\n* Tuberculosis or other infectious etiology\n* Secondary spontaneous pneumothorax (COPD, cancer, cystic fibrosis, connective tissue disease, sarcoidosis, catamenial, etc.)\n* Pneumothorax due to trauma\n* Hemothorax or hydropneumothorax\n* Immunocompromised subjects: neutropenic, leukopenia, or subjects taking immunosuppressive medication such as chemotherapy, transplant medications, steroid (≥5 mg of prednisone or equivalent), etc.\n* Interstitial lung disease\n* Children (\\\u003C18)\n* Pregnant women\n* Adults unable to consent for themselves\n* Prisoners",{"count":82,"type":21},200,[24],"Video-assisted thoracoscopic surgery (VATS) with blebectomy\u002Fwedge resection plus pleurodesis is the standard of care for recurrent primary spontaneous pneumothorax (PSP) or, in certain instances, after the first episode. The chest tube from surgery is typically kept to suction until post-operative day (POD) 2 to allow for scarring of the lung to the chest to prevent recurrence. However, the scarring process takes place over a period of weeks and is there no data to support POD#2 as the best time to remove the chest tube. Also, shorter chest tube duration can lower length of stay, patient discomfort, and hospital cost.\n\nThe goal of this randomized study is to determine if early removal (POD#1) of chest tube after video-assisted thoracoscopic surgery (VATS) with blebectomy\u002Fwedge resection plus chemical pleurodesis for primary spontaneous pneumothorax (PSP):\n\n* has no worse 2-year recurrence rate compared to standard removal (POD#2)\n* will lower length of stay compared to standard removal\n* will result in less complications or re-interventions compared to standard removal\n\nParticipants will be asked to join prior to surgery. Following standard-of-care surgery, participants will be screened for randomization. If still eligible, participants will be randomized for early chest tube removal or standard removal. Early Removal will happen within 24 hours after surgery, with Standard Removal happening day 2 after surgery.\n\nParticipants will follow-up with the study team for 2 years on the following schedule:\n\n* In clinic with a chest x-ray 2 weeks after surgery\n* By phone 3 months after surgery\n* In clinic with a chest x-ray 1 year after surgery\n* In clinic with a chest x-ray 2 years after surgery",[86],"Primary Spontaneous Pneumothorax","2025-05-13",{"date":89,"type":41},"2025-05-16",{"date":91,"type":41},"2023-10-03",{"date":45,"type":21},{"name":47,"class":48},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":112,"locationsCount":74},"100468482","early-phase-1-personalized-cancer-stem-cell-high-throughput-drug-screening-for-glioblastoma-100468482","NCT05380349","Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma","A Phase 1 Study of Combination Drug Therapy Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS) With Standard of Care for Newly Diagnosed Glioblastoma","Inclusion Criteria:\n\n* Histological diagnosis of GBM (WHO grade 4)\n* Subjects ≥18 years of age\n* Patients must have a life expectancy of \\>6 months\n* Patients must have a surgically accessible tumor with the intent for a gross or near total resection of the tumor mass (GBM, WHO grade 4)\n* Patients must have a KPS rating of ≥70\n* Patients should not have received any prior systemic anti-cancer therapy\n* Patients must be negative for HIV, Hepatitis B and C\n* Baseline hematologic studies and chemistry and coagulation profiles must meet the following criteria:\n\n  * Hemoglobin (Hgb)\\> 8 g\u002FdL\n  * Absolute Neutrophil Count (ANC) \\> 1,000\u002Fmm3\n  * Platelet count \\> 100,000\u002Fmm3\n  * Creatinine \\\u003C 2 mg\u002FdL\n  * Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \\\u003C 3x upper limit of normal (ULN)\n\nExclusion Criteria:\n\n* Metastatic disease\n* Diseases or conditions that obscure toxicity or dangerously alter drug metabolism\n* Serious intercurrent medical illness\n* Inadequately controlled hypertension\n* History of myocardial infarction or unstable angina within 6 months\n* History of stroke or transient ischemic attack within 6 months",{"count":102,"type":21},10,[104],"EARLY_PHASE1","Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.",[107],"Newly Diagnosed Glioblastoma",{"date":89,"type":41},{"date":110,"type":41},"2024-04-19",{"date":45,"type":21},{"name":47,"class":48},""]